ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2011
RANKL inhibition: a promising novel strategy for breast cancer treatment.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Association between dietary acid load and cancer risk and prognosis: An updated systematic review and meta-analysis of observational studies.Frontiers in nutrition · 2022Pooled it
- OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.Molecular oncology · 2014Pooled it
- SFRP1 Expression is Inversely Associated With Metastasis Formation in Canine Mammary Tumours.Journal of mammary gland biology and neoplasia · 2023Article
- Review
- p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling.Breast cancer research : BCR · 2019Article
- Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women.Cancer prevention research (Philadelphia, Pa.) · 2018Observational
- Article
- The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages.The Journal of investigative dermatology · 2015Article
- Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.PloS one · 2015Article
- Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis.Cancer science · 2015Article
- RANK expression on breast cancer cells promotes skeletal metastasis.Clinical & experimental metastasis · 2014Article
- Examining the relationship between diet-induced acidosis and cancer.Nutrition & metabolism · 2012Article
- Notch and Mef2 synergize to promote proliferation and metastasis through JNK signal activation in Drosophila.The EMBO journal · 2012Article
- The biology of progesterone receptor in the normal mammary gland and in breast cancer.Molecular and cellular endocrinology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cytokine RANKL and its receptor RANK, key proteins in bone remodelling and bone metastasis, are essential for mammary gland development in mice. RANK absence or overexpression results in a lactation defect and a non-functional mammary gland. RANKL signalling mediates progesterone-induced proliferation and expansion of the stem cell compartment in the mouse mammary gland. RANK overexpressing mammary epithelial acini show hallmarks of transformation in a RANKL-dependent manner. Complementary gain- and loss-of-function approaches (RANK transgenic and knock-out mouse models and pharmacological RANKL inhibition) define a direct contribution of this pathway to progestin-driven mammary cancer. Moreover, decreased RANKL signalling attenuates preneoplasic lesions and lung metastasis in the spontaneous model of mammary tumorigenesis MMTV-neu, suggesting that RANK pathway promotes mammary tumorigenesis and metastasis in a wider tumour spectrum and beyond its established role in bone metastasis. In this review, we summarise the role of the RANKL pathway in mammary gland development, breast cancer and metastasis, and discuss the potential application of RANKL inhibition for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.